Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05730725 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT05730725 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 109 participants.
The verdict
NCT05730725, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
Interventions
- OTHER Placebo
- DRUG BMS-986322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05730725
The ClinicalTrials.gov registry entry for NCT05730725 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05730725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05730725 about?
NCT05730725 is a clinical study titled "A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis". The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
What is the current status of trial NCT05730725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2023-04-03. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT05730725?
The interventions under investigation include: Placebo (OTHER), BMS-986322 (DRUG).
Who is sponsoring clinical trial NCT05730725?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.